New radiotherapy technique aims to protect the heart during lung cancer treatment

Learning from Every Patient: New Radiotherapy Technique Aims to Protect the Heart During Lung Cancer Treatment

Vienna, Austria – A new study presented at ESTRO 2025 introduces the RAPID-RT study, which uses an innovative rapid-learning approach to evaluate the impact of treatment modifications in radiotherapy. Traditional clinical trials are often lengthy and are not representative of real-world patient populations due to complex consent processes and strict eligibility criteria. In contrast, RAPID-RT offers a more inclusive, real-world alternative. Researchers at The Christie NHS Foundation Trust in Manchester, UK, have applied this method in lung cancer patients to assess whether reducing the dose to the top of the heart—a hypothesised risk area, can improve survival by minimising cardiac toxicity associated with conventional radiotherapy.

Targeting Tumours, Protecting the Heart

Radiotherapy is a highly effective treatment for lung cancer, yet the heart is often located close to the tumour site. It is important that the dose to the heart is minimised to reduce the risk of serious complications. Previous research in Manchester using radiotherapy planning images identified the top of the heart as a particularly radiosensitive area in lung cancer patients, with radiation dose to this region found to be associated with overall survival.

Based on these results, a new "heart-sparing" technique was implemented in the routine clinical setting to address this challenge.

“RAPID-RT represents a shift towards more inclusive research, designed to reflect the realities of everyday clinical practice and ensure that all patients, not just those who meet narrow trial criteria, benefit from innovation in radiotherapy” said co-lead investigator Dr Gareth Price, senior lecturer and medical physicist, at the University of Manchester.

“We also hope that by reducing cardiac exposure, we may improve both survival and quality of life for patients.”

Key Data from Over 1,700 Patients

The RAPID-RT study analysed data from 1,708 patients with stage I–III lung cancer who received curative-intent radiotherapy between January 2021 and February 2025:

Standard curative-intent radiotherapy treatment was given to 922 patients treated before April 2023. The new heart-sparing technique was applied prospectively to 786 patients from April 2023 onwards, using two key innovations: An inclusive rapid-learning study design:  this approach enables fast recruitment by including all patients treated at the institution, unless they actively opt out of data collection. Limiting radiation to a defined Cardiac Avoidance Area (CAA): Radiation dose to sensitive parts of the heart was limited to at 19.5 Gy (or equivalent) over 20-33 sessions, unless this restriction compromised adequate tumour coverage Early results show that the rapid-learning method is highly inclusive as to date all patients with stage 1-3 NSCLC treated with conventional curative-intent radiotherapy received the new technique, with only 1 out of 786 patients choosing to opt out of the study. Initial findings suggest a modest improvement in 12-month survival following implementation of a dose limit to the top of the heart. Faster Answers with Real-World Evidence

Unlike traditional clinical trials, which can take years to deliver results, the RAPID-RT study used a "rapid-learning" model, to evaluate and adapt treatments in real time using routine anonymised data from the electronic care record. This approach allows researchers to refine treatment strategies more quickly, bringing effective innovations to patients faster.

“This research is a perfect example of how innovation in radiotherapy is not only about technology, but also about how we learn, adapt, and deliver better care,” said Professor Matthias Guckenberger, President of ESTRO and Chair of Radiation Oncology at the University Hospital Zurich.

“It demonstrates the power of combining cutting-edge technology with real-world data to make radiotherapy safer and even more effective.”

Towards Smarter, More Inclusive Evaluation of Radiotherapy Modifications

RAPID-RT represents an important step towards more inclusive and pragmatic clinical trials in radiotherapy. The study provides compelling evidence that novel trial methods can effectively evaluate treatment modifications, especially in situations where traditional randomised trials are not feasible.

The study will continue to recruit and follow patients’ progress to confirm these early results and allow clinical teams to decide if patients might benefit from further refinement of the new radiotherapy technique. Ongoing analyses will assess the potential impact on long-term survival, radiotherapy-related toxicities, and explore alternative modelling approaches to better understand treatment outcomes.

(ends)

Abstract n° E25-5022: “First RAPID-RT analysis: Using rapid-learning to assess the survival impact of a new cardiac avoidance area during lung cancer radiotherapy”, presented on Monday 5 May at 17:40 hrs (CEST), Plenary Hall.

Note: When obtaining outside comment, journalists are requested to ensure that their contacts are aware of the embargo on this release.

About ESTRO 2025

ESTRO 2025 brings together around 7,000 participants from over 80 countries, showcasing the latest research in clinical radiation oncology, radiobiology, medical physics, technology, and brachytherapy. Leading doctors and scientists from around the world present groundbreaking findings, in line with the conference theme: “Transformative innovation through collaboration”.

ESTRO 2025 is the annual congress of the European Society for Radiotherapy and Oncology (ESTRO), an organisation dedicated to advancing cancer treatment through radiotherapy and multimodal approaches. ESTRO promotes education, science, and research and advocates for universal access to radiotherapy. With nearly 10,000 members worldwide, it supports radiation oncology professionals and the broader oncology community in their daily practice.

END